Arcus Biosciences, Inc. reported financial results for three months ended March 31, 2026.
“On May 5, 2026 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.”
Arcus Biosciences, Inc. — fact timeline
Source-grounded facts extracted from Arcus Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcus Biosciences, Inc. amended credit facility of $150.0 million term loan commitments with Hercules Capital, Inc. maturing September 1, 2030.
“Agreement, dated as of August 27, 2024, by and among the Company, Hercules and the Lenders (the “Loan Agreement”). The First Amendment amends the terms for the remaining $150.0 million term loan commitments available under the loan facility such that, subject to customary terms and conditions, (a) $25.0 million is available at the Company's sole option through”
Dietmar Berger was appointed as Class II Director at Arcus Biosciences, Inc..
“On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.”
Merdad Parsey resigned as Director at Arcus Biosciences, Inc..
“On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.”
Dimitry Nuyten departed as Chief Medical Officer at Arcus Biosciences, Inc..
“Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025”
Richard Markus was appointed as Chief Medical Officer at Arcus Biosciences, Inc..
“Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025”
Arcus Biosciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $145 million.
“to fund operations into 2027. Cash, cash equivalents and marketable securities are expected to be between $870 million and $920 million at the end of 2024. • Revenues were $145 million for the first quarter 2024, compared to $25 million for the same period in 2023. In the first quarter 2024, Arcus recognized $135 million in license and development services”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.